Aromatic interactions with phenylalanine 691 and cysteine 828: A concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents

被引:26
作者
Furet, Pascal [1 ]
Bold, Guido [1 ]
Meyer, Thomas [1 ]
Roesel, Johannes [1 ]
Guagnano, Vito [1 ]
机构
[1] Novartis Pharma AG, Novartis Inst Biomed Res, CH-4002 Basel, Switzerland
关键词
D O I
10.1021/jm060368s
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
FLT3 kinase inhibitors are currently under investigation as a new treatment for acute myeloid leukemia. We report here a molecular concept invoking interactions between an aromatic ring and the side chains of Phe691 and Cys828, two residues of the ATP pocket, to obtain potent and specific inhibitors of this kinase. The hypothesis has been validated by the successful design of a new inhibitor prototype showing promising antiproliferative activity in cellular assays.
引用
收藏
页码:4451 / 4454
页数:4
相关论文
共 20 条
[1]   FLT3 and acute myelogenous leukemia: Biology, clinical significance and therapeutic applications [J].
Advani, AS .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (26) :3449-3457
[2]   Recent kinase and kinase inhibitor X-ray structures: Mechanisms of inhibition and selectivity insights [J].
Cherry, M ;
Williams, DH .
CURRENT MEDICINAL CHEMISTRY, 2004, 11 (06) :663-673
[3]   Characterization of aromatic-thiol π-type hydrogen bonding and phenylalanine-cysteine side chain interactions through ab initio calculations and protein database analyses [J].
Duan, GL ;
Smith, VH ;
Weaver, DF .
MOLECULAR PHYSICS, 2001, 99 (19) :1689-1699
[4]   The roles of FLT3 in hematopoiesis and leukemia [J].
Gilliland, DG ;
Griffin, JD .
BLOOD, 2002, 100 (05) :1532-1542
[5]   The structural basis for autoinhibition of FLT3 by the juxtamembrane domain [J].
Griffith, J ;
Black, J ;
Faerman, C ;
Swenson, L ;
Wynn, M ;
Lu, F ;
Lippke, J ;
Saxena, K .
MOLECULAR CELL, 2004, 13 (02) :169-178
[6]  
HANKS SK, 1991, METHOD ENZYMOL, V200, P38
[7]   Targeting FLT3 kinase in acute myelogenous leukemia: Progress, perils, and prospects [J].
Heinrich, MC .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (03) :255-271
[8]   Novel FLT3 tyrosine kinase inhibitors [J].
Levis, M ;
Small, D .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (12) :1951-1962
[9]   A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations [J].
Levis, M ;
Tse, KF ;
Smith, BD ;
Garrett, E ;
Small, D .
BLOOD, 2001, 98 (03) :885-887
[10]  
LEWIS M, 2003, LEUKEMIA, V17, P1738